Evidence map›Paper›PMID 37235704›Full record

Trial reportJMIR public health and surveillance2023

Comparison of Four Active SARS-CoV-2 Surveillance Strategies in Representative Population Sample Points: Two-Factor Factorial Randomized Controlled Trial.

Andreas Deckert, Simon Anders, Ivonne Morales, Manuela De Allegri, Hoa Thi Nguyen, Aurélia Souares, Shannon McMahon, Matthias Meurer, Robin Burk, Dan Lou and 15 more

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JMIR public health and surveillance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Andreas DeckertHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0003-0526-6249
Simon AndersCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0000-0003-4868-1805
Ivonne MoralesDivision of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-6803-9284
Manuela De AllegriHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0002-8677-1337
Hoa Thi NguyenHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0001-9626-2934
Aurélia SouaresHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0002-3984-5866
Shannon McMahonHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0002-8634-9283
Matthias MeurerCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0000-0003-4651-128X
Robin BurkCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0000-0003-4651-6486
Dan LouCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0009-0008-6154-1341
Lucia Brugnaraevaplan GmbH at the University Hospital, Heidelberg, Germany.ORCID 0000-0001-5708-7301
Matthias SandGESIS Leibniz-Institute for the Social Sciences, Mannheim, Germany.ORCID 0009-0009-0092-4522
Lisa KoeppelDivision of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0003-4445-7881
Lena Maier-HeinDivision of Computer Assisted Medical Interventions, German Cancer Research Centre, Heidelberg, Germany.ORCID 0000-0003-4910-9368
Tobias RossDivision of Computer Assisted Medical Interventions, German Cancer Research Centre, Heidelberg, Germany.ORCID 0000-0002-7094-4926
Tim J AdlerDivision of Computer Assisted Medical Interventions, German Cancer Research Centre, Heidelberg, Germany.ORCID 0000-0002-3424-6629
Stephan BrennerHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0001-5397-7008
Christopher DyerGesundheitsamt des Rhein-Neckar-Kreises, Heidelberg, Germany.ORCID 0000-0003-1651-5511
Konrad HerbstCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0000-0003-1296-1522
Svetlana OvchinnikovaCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0000-0001-9157-2634
Michael Marxevaplan GmbH at the University Hospital, Heidelberg, Germany.ORCID 0000-0002-2342-7002
Paul SchnitzlerCenter of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-5503-3801
Michael KnopCenter for Molecular Biology Heidelberg, Heidelberg, Germany.ORCID 0000-0003-2566-923X
Till BärnighausenHeidelberg Institute of Global Health, Heidelberg, Germany.ORCID 0000-0002-4182-4212
Claudia M DenkingerDivision of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-7216-7067
Heidelberg University · DEGerman Cancer Research Center · DEGESIS - Leibniz-Institute for the Social Sciences · DEGesundheitsamt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic is characterized by rapid increases in infection burden owing to the emergence of new variants with higher transmissibility and immune escape. To date, monitoring the COVID-19 pandemic has mainly relied on passive surveillance, yielding biased epidemiological measures owing to the disproportionate number of undetected asymptomatic cases. Active surveillance could provide accurate estimates of the true prevalence to forecast the evolution of the pandemic, enabling evidence-based decision-making.

objectiveThis study compared 4 different approaches of active SARS-CoV-2 surveillance focusing on feasibility and epidemiological outcomes.

methodsA 2-factor factorial randomized controlled trial was conducted in 2020 in a German district with 700,000 inhabitants. The epidemiological outcome comprised SARS-CoV-2 prevalence and its precision. The 4 study arms combined 2 factors: individuals versus households and direct testing versus testing conditioned on symptom prescreening. Individuals aged ≥7 years were eligible. Altogether, 27,908 addresses from 51 municipalities were randomly allocated to the arms and 15 consecutive recruitment weekdays. Data collection and logistics were highly digitized, and a website in 5 languages enabled low-barrier registration and tracking of results. Gargle sample collection kits were sent by post. Participants collected a gargle sample at home and mailed it to the laboratory. Samples were analyzed with reverse transcription loop-mediated isothermal amplification (RT-LAMP); positive and weak results were confirmed with real-time reverse transcription-polymerase chain reaction (RT-PCR).

resultsRecruitment was conducted between November 18 and December 11, 2020. The response rates in the 4 arms varied between 34.31% (2340/6821) and 41.17% (2043/4962). The prescreening classified 16.61% (1207/7266) of the patients as COVID-19 symptomatic. Altogether, 4232 persons without prescreening and 7623 participating in the prescreening provided 5351 gargle samples, of which 5319 (99.4%) could be analyzed. This yielded 17 confirmed SARS-CoV-2 infections and a combined prevalence of 0.36% (95% CI 0.14%-0.59%) in the arms without prescreening and 0.05% (95% CI 0.00%-0.108%) in the arms with prescreening (initial contacts only). Specifically, we found a prevalence of 0.31% (95% CI 0.06%-0.58%) for individuals and 0.35% (95% CI 0.09%-0.61%) for households, and lower estimates with prescreening (0.07%, 95% CI 0.0%-0.15% for individuals and 0.02%, 95% CI 0.0%-0.06% for households). Asymptomatic infections occurred in 27% (3/11) of the positive cases with symptom data. The 2 arms without prescreening performed the best regarding effectiveness and accuracy.

conclusionsThis study showed that postal mailing of gargle sample kits and returning home-based self-collected liquid gargle samples followed by high-sensitivity RT-LAMP analysis is a feasible way to conduct active SARS-CoV-2 population surveillance without burdening routine diagnostic testing. Efforts to improve participation rates and integration into the public health system may increase the potential to monitor the course of the pandemic.

trial registrationDeutsches Register Klinischer Studien (DRKS) DRKS00023271; https://tinyurl.com/3xenz68a. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1186/s13063-021-05619-5.

Indexed as

COVID-19SARS-CoV-2HumansLaboratoriesPandemicsSpecimen Handlingcluster samplingCOVID-19effectivenessmultiarmpandemicrandomized controlled trialSARS-CoV-2surveillance

Identifiers

PMID37235704
PMCPMC10437130
OpenAlexW4378473038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.